The Patent Finder

Espero Biopharma, Inc.

Also on record
Records under this name other than patents Espero Biopharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Espero Biopharma, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,498,449Antiarrhythmic Precursor Compounds, Methods of Synthesis and Methods of Use
now held by Xyra, LLC
In force
 · High confidence
In forceHigh confidence
US 9,549,912Methods for Treating Atrial Fibrillation
now held by Xyra, LLC
In force (reinstated)
 · Medium confidence
In force (reinstated)Medium confidence
US 7,105,568Novel Compounds for Treatment of Cardiac Arrhythmia and Methods of Use
now held by Hesp LLC
Term ended
Term ended Apr 8, 2025 · High confidence
Term endedTerm ended Apr 8, 2025High confidence
US 6,869,972Novel Compounds for Treatment of Cardiac Arrhythmia, Synthesis, and Methods of Use
now held by Hesp LLC
Term ended
Term ended Dec 10, 2022 · High confidence
Term endedTerm ended Dec 10, 2022High confidence
US 7,037,933Novel Compounds for Treatment of Cardiac Arrhythmia, Synthesis, and Methods of Use
now held by Hesp LLC
Term ended
Term ended Dec 10, 2022 · Medium confidence
Term endedTerm ended Dec 10, 2022Medium confidence
US 7,145,020Materials and Methods for Treating Coagulation Disorders
Term ended
Ended no later than Apr 24, 2022 · Low confidence
Term endedEnded no later than Apr 24, 2022Low confidence
US 7,253,208Materials and Methods for Treating Coagulation Disorders
Term ended
Ended no later than Apr 24, 2022 · Low confidence
Term endedEnded no later than Apr 24, 2022Low confidence
US 7,285,671Materials and Methods for Treating Coagulation Disorders
Term ended
Ended no later than Apr 24, 2022 · Low confidence
Term endedEnded no later than Apr 24, 2022Low confidence
US 7,666,902Haloalkyl Ester Derivatives of Coumarin for the Treatment of Coagulation Disorders
Term ended
Term ended Apr 24, 2022 · Medium confidence
Term endedTerm ended Apr 24, 2022Medium confidence
US 7,932,405Halogenated Ester Derivatives of Coumarins for the Treatment of Coagulation Disorders
Term ended
Term ended Apr 24, 2022 · Medium confidence
Term endedTerm ended Apr 24, 2022Medium confidence
10 of 13 records shown.
Pro members see all 13.
Pro members: see all 13 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited